Jonathan Fox received his BA (Biology), PhD (Pathology), and MD degrees from the University of Chicago. He completed postgraduate training in internal medicine and cardiology at Duke University, where he worked in the laboratory of Dr Judith Swain, studying myocyte cell biology and growth factor signal transduction.

Following his postgraduate training, Dr. Fox was appointed Assistant Professor of Medicine (Cardiology) at the University of Pennsylvania. There he combined his interest in atherosclerosis with his work in myocyte cell biology to craft an independent research program in vascular biology, focusing on the role of growth factors, cellular signaling, and programmed cell death in atherogenesis.

In 1998, Dr. Fox was recruited to SmithKline Beecham Pharmaceuticals’ Clinical Pharmacology and Experimental Medicine group where he worked on the development of therapeuties for diabetes, arrhythmias, atherosclerosis, and restenosis. He then moved to Merck Research Laboratories where he worked in early phase development in thrombosis, diabetes and arrhythmia, and on large outcomes trials in heart failure, hypertension and diabetes. He then joined AstraZeneca where he initially led global Phase3B efforts in dyslipidemia and cardiovascular outcomes, and later the Phase3 registration program for ticagrelor, an antiplatelet agent for acute coronary syndromes. As Vice President, Clinical Development he led the clinical development research group for the entire cardiovascular, metabolic, and gastrointestinal products portfolio. In these industry roles he has participated in a broad variety of product registration filings in the US, EU, Japan and other global markets.

In January, 2013 Dr. Fox was appointed Chief Medical Officer at MyoKardia, a Bay Area biotechnology company developing novel therapeutics targeting genetic cardiomyopathies. He is a longstanding Trustee of the Lankenau Institute for Medical Research in Wynnewood, PA, and completed a four-year term as the Industry Representative to the FDA's Cardiovascular and Renal Drug Products Advisory Committee. He looks forward to bringing his own combination of basic science interests, clinical background, and extensive drug development experience to his role as consulting faculty, with the goal of helping other medical scientists understand and successfully navigate the complex road from creative idea to therapeutic reality.